US Antibiotic Incentives Extended To Drugs That Prevent Or Diagnose Infections

Law defines QIDP as antibacterials and antifungals intended to 'treat' serious infections, but FDA now interprets provision more broadly to include preventive and diagnostic products, agency says in a new draft guidance clarifying program's requirements and benefits for sponsors

Antibacterial and antifungal drugs intended to prevent or diagnose a serious or life-threatening infection are eligible for designation as a Qualified Infectious Disease Product (QIDP), US FDA says in a new draft guidance document.

However, the guidance confirms that QIDP status extends only to small molecules, and not biologic products or devices.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards